Bristol-Myers Squibb

Currency swings cost U.S. corporates $18.66 billion in fourth quarter: study

Foreign exchange swings cost North American corporates $18.66 billion in revenue in the fourth quarter, according to a report by currency risk management consulting firm FiREapps.

Read Full Article

AstraZeneca strengthens cancer business with new deals

AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.

Read Full Article

U.S. approval of Merck cancer immunotherapy expected soon

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

Read Full Article

Pharmaceutical firms introduce new drugs but encounter selling difficulties- report

After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.

Read Full Article

Bristol-Myers Squibb to exit diabetes joint venture - Citi analyst

An announcement made last Thursday of a realignment in priority drug research projects prompted Citi analyst to advise shareholders of a possible interest divestment in diabetes drug joint venture between Bristol-Myers Squibb and AstraZeneca.

Read Full Article

Bristol-Myers Executive, Ramnarine Admits Insider Trading

Robert Ramnarine, former Bristol-Myers executive pleaded guilty to the insider trading charges filed against him.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics